Get the Stockscreener App
3.97
1.49%
-0.06
Orasure Technologies Inc stock is traded at $3.97, with a volume of 298.00K.
It is down -1.49% in the last 24 hours and down -8.53% over the past month.
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
See More
Previous Close:
$4.03
Open:
$4.04
24h Volume:
298.00K
Relative Volume:
0.47
Market Cap:
$273.33M
Revenue:
$113.02M
Net Income/Loss:
$-75.07M
P/E Ratio:
-3.8074
EPS:
-1.0427
Net Cash Flow:
$-47.88M
1W Performance:
+2.58%
1M Performance:
-8.53%
6M Performance:
+48.69%
1Y Performance:
+19.58%
1-Day Range:
$3.96
$4.098
1-Week Range:
$3.705
$4.098
52-Week Range:
$2.08
$4.58
Orasure Technologies Inc Stock (OSUR) Company Profile
Name
Orasure Technologies Inc
Sector
Industry
Phone
(503) 641-6115
Address
220 E FIRST ST, BETHLEHEM, PA
Compare OSUR vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OSUR
Orasure Technologies Inc
|
3.97 | 273.33M | 113.02M | -75.07M | -47.88M | -1.0427 |
ISRG
Intuitive Surgical Inc
|
337.50 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
156.36 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.91 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
38.75 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
195.27 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Orasure Technologies Inc Stock (OSUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-23 | Resumed | Evercore ISI | In-line |
| Sep-22-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-21-20 | Initiated | Evercore ISI | Outperform |
| Aug-10-20 | Initiated | Citigroup | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
| Aug-07-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-25-20 | Initiated | Lake Street | Buy |
| Apr-21-20 | Resumed | Stephens | Equal-Weight |
| Oct-23-18 | Resumed | Raymond James | Mkt Perform |
| Jul-16-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-02-17 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-13-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-05-15 | Reiterated | Mizuho | Buy |
| May-07-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jan-23-15 | Reiterated | Mizuho | Buy |
| Jun-12-14 | Reiterated | Canaccord Genuity | Buy |
| Jun-11-14 | Reiterated | Mizuho | Buy |
| Dec-21-12 | Initiated | Mizuho | Buy |
| Aug-08-12 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-05-12 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-27-12 | Initiated | JMP Securities | Mkt Outperform |
View All
Orasure Technologies Inc Stock (OSUR) Latest News
OraSure Technologies Inc (OSUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OraSure Technologies, Inc. Revenue Breakdown – LSX:881351 - TradingView
OraSure Technologies, Inc. Revenue Breakdown – TRADEGATE:EP3 - TradingView
3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Enterprise value to revenue forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
OraSure to announce Q2 2026 financial results on August 5 - scanx.trade
OraSure's Q2 results webcast is set for Aug. 5 after market close - Stock Titan
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th - Moomoo
Bethlehem’s OraSure gets FDA emergency authorization for Ebola test - Lehigh Valley Business
OraSure wins FDA emergency nod for Ebola test (OSUR:NASDAQ) - Seeking Alpha
OraSure receives Emergency Use Authorization for second generation Ebola test - WFMZ.com
Why Has OraSure Technologies (NASDAQ:OSUR) Entered Nasdaq News? - Kalkine Media
OraSure (OSUR) Secures FDA Approval for Enhanced Ebola Rapid Tes - GuruFocus
OraSure Technologies Gets Emergency Use Authorization From FDA for New Ebola Test - marketscreener.com
OraSure Receives Emergency Use Authorization for Second Generation Ebola Test - The Manila Times
Enterprise value to revenue forward of OraSure Technologies, Inc. – MUN:EP3 - TradingView
OraSure Technologies (OSUR) Slides 6.8% as Shares Test Critical Support Near $3.76Single Stock ETF - dars.gov.et
Bethlehem's OraSure puts another property up for sale - WFMZ.com
OraSure Technologies stock holds steady as diagnostics business targets growth - AD HOC NEWS
OraSure Technologies updates highlight diagnostics focus amid shifting health trends - ad-hoc-news.de
OSUR Q1 2026 Earnings: Significant Earnings Miss as Losses WidenSaaS Earnings Trends - DonanımHaber
OSUROrasure Technologies Inc Latest SEC Filings - Finviz
Form 4 OraSure Technologies Inc For: 30 June By Investing.com - Investing.com Nigeria
OraSure Technologies (OSUR) director takes 3,666-share stock grant in lieu of cash - Stock Titan
Enterprise value to EBIT forward of OraSure Technologies, Inc. – MUN:EP3 - TradingView
Price to earnings forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to book forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to book forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Price to sales forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to sales forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Enterprise value to revenue forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Price to earnings forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Enterprise value to EBITDA forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
OraSure Technologies Q1 2026 Earnings: EPS Misses Estimates as Stock Declines Over 4.9%Quarterly Earnings - DonanımHaber
OraSure gets FDA nod for at-home STI urine collection kit - Investing.com Nigeria
3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
OraSure Technologies Hits New 52-Week High of $4.36, Marking Significant Growth - MarketsMojo
OraSure Technologies Inc (OSUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OraSure Technologies Inc (OSUR) Institutional Confidence - TradingKey
OraSure Technologies Inc (OSUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
OraSure Technologies Inc (OSUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OraSure Technologies Inc (OSUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OraSure Technologies Inc (OSUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OraSure Technologies Inc (OSUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OraSure Wins FDA Clearance for At-Home STI Collection - The Globe and Mail
OraSure receives FDA clearance for home urine collection kit for STIs - Lehigh Valley Business
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Yahoo Finance
FDA Clears Home Urine Collection Kit for STI Testing - Conexiant
OraSure secures FDA clearance for product seen as key to future growth - WFMZ.com
OraSure stock jumps on FDA clearance for at-home STI kit - Investing.com
Orasure Technologies Inc Stock (OSUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orasure Technologies Inc Stock (OSUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyd Steven Kyle | Director |
May 14 '26 |
Buy |
2.99 |
25,000 |
74,750 |
113,462 |
| Boyd Steven Kyle | Director |
May 12 '26 |
Buy |
2.98 |
25,000 |
74,500 |
63,462 |
| McGrath Kenneth J | Chief Financial Officer |
Mar 20 '26 |
Buy |
2.93 |
32,300 |
94,600 |
589,562 |
| EGLINTON MANNER CARRIE | President & CEO |
Mar 20 '26 |
Buy |
2.93 |
32,300 |
94,597 |
2,190,874 |
| McGrath Kenneth J | Chief Financial Officer |
Mar 13 '26 |
Buy |
3.00 |
22,021 |
66,030 |
557,262 |
| EGLINTON MANNER CARRIE | President & CEO |
Mar 13 '26 |
Buy |
3.00 |
22,022 |
66,033 |
2,158,574 |
3.37%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):